Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis
Cells · 2025
DOI: 10.3390/cells14090625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Carlos Zamora und 12 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Diseases, Institut Recerca Hospital Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, CD40 Ligand, Blood Platelets, Immunomodulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Instituto de Salud Carlos III and Fondos FEDER.
Abstract (Originalsprache)
Background
Platelets (PLTs) from healthy donors (HD) modulate T lymphocyte responses but PLTs from rheumatoid arthritis (RA) patients contribute to persistent systemic inflammation. This suggests that PLTs from RA patients and HD have different immunomodulatory effects.
Methods
Using cell culture, flow cytometry, proteomics, and ELISA, we compared PLTs from HD and RA patients and their effects on T lymphocyte activation and cytokine production.
Results
HD PLTs suppressed T lymphocyte proliferation and IFNγ and TNF production, while RA PLTs exhibited reduced suppressive capacity. In the presence of RA PLTs, IFNγ levels correlated with T lymphocyte proliferation, greater disease activity, and anti-citrullinated protein antibodies (ACPA). Proteomic analysis revealed that RA PLTs show upregulation of proteins linked to acute-phase response and complement activation. RA PLTs secreted higher levels of soluble CD40L (sCD40L) and PDGF-BB that correlated with enhanced IFNγ production. Seropositive RA patients had higher levels of sCD40L, and these levels were predictive of disease remission in RA patients treated with anti-IL6R. sCD40L was found to enhance T lymphocyte activation and to contribute to increased pro-inflammatory cytokine production.
Conclusions
This study highlights the diminished ability of RA PLTs to suppress T lymphocyte activation and that sCD40L can be a potential biomarker and therapeutic target in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Diseases, Institut Recerca Hospital Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
- Rheumatology Department, Hospital Santa Creu I Sant Pau, 08041 Barcelona, Spain.
- Institut Recerca Hospital Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
- Centre Medic Teknon, 08022 Barcelona, Spain.
- Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain.
ORCID-Profile: Cesar Diaz-Torne, Maria Angels Ortiz, Patricia Moya, Ruben Osuna-Gomez, Maria Mulet, Hector Corominas, Silvia Vidal
Förderung
- Instituto de Salud Carlos III
- Instituto de Salud Carlos III and Fondos FEDER
Zitieren
APA
Zamora, C., Diaz-Torne, C., Ortiz, M. A., Moya, P., Park, H. S., Pitarch, C., Cantó, E., Osuna-Gomez, R., Mulet, M., Garcia-Arguinzonis, M., Collado, D., Corominas, H., & Vidal, S. (2025). Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells. https://doi.org/10.3390/cells14090625
Vancouver
Zamora C, Diaz-Torne C, Ortiz MA, Moya P, Park HS, Pitarch C, et al. Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells. 2025. doi:10.3390/cells14090625
BibTeX
@article{Zamora2025,
author = {Zamora, Carlos and Diaz-Torne, Cesar and Ortiz, Maria Angels and Moya, Patricia and Park, Hye Sang and Pitarch, Concepció and Cantó, Elisabet and Osuna-Gomez, Ruben and Mulet, Maria and Garcia-Arguinzonis, Maisa and Collado, Diego and Corominas, Hector and Vidal, Silvia},
title = {Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14090625}
}
EUVIMED